CeriBell (NASDAQ:CBLL) VP David Foehr Sells 859 Shares

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 859 shares of CeriBell stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $23.95, for a total transaction of $20,573.05. Following the sale, the vice president directly owned 35,899 shares of the company’s stock, valued at $859,781.05. This represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $23,851.86.

CeriBell Stock Up 0.0%

Shares of CBLL traded up $0.01 during midday trading on Tuesday, reaching $23.95. 243,381 shares of the stock were exchanged, compared to its average volume of 457,237. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The company’s 50 day moving average is $19.77 and its two-hundred day moving average is $19.27. The company has a market capitalization of $919.20 million, a P/E ratio of -13.61 and a beta of 0.81. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, sell-side analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Institutional Trading of CeriBell

Several hedge funds have recently modified their holdings of CBLL. Russell Investments Group Ltd. boosted its holdings in CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after purchasing an additional 854 shares during the period. Sei Investments Co. increased its holdings in CeriBell by 2.3% during the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the period. Caitong International Asset Management Co. Ltd raised its position in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after buying an additional 1,393 shares during the period. Finally, Strs Ohio purchased a new position in shares of CeriBell in the 1st quarter valued at about $27,000.

Wall Street Analyst Weigh In

Several research analysts recently commented on CBLL shares. Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group lifted their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. BTIG Research increased their price objective on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.